-
公开(公告)号：US20070117807A1
公开(公告)日：2007-05-24
申请号：US11558132
申请日：2006-11-09
IPC分类号： A61K31/501 , A61K31/4965 , A61K31/497 , C07D403/02
CPC分类号： C07D207/335 , C07C311/08 , C07C311/21 , C07C311/29 , C07C311/44 , C07C2601/02 , C07C2601/14 , C07D213/40 , C07D213/64 , C07D215/12 , C07D231/12 , C07D231/16 , C07D233/56 , C07D233/64 , C07D235/14 , C07D249/08 , C07D277/28 , C07D307/14 , C07D307/52 , C07D405/12
摘要： The present invention is related to a process for preparing anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).
摘要翻译： 本发明涉及制备式I的邻氨基苯甲酰胺的方法，其中R（1）至R（7）具有本文所指的含义，其制备方法，其作为药物的用途以及含有它们的药物制剂。 化合物作用于Kv1.5钾通道并抑制在人心脏中心被称为超快速活化延迟整流器的钾电流。 因此，该化合物适合用作新的抗心律不齐剂，用于治疗和预防心律失常（例如心房颤动（AF）或心房扑动））。
-
公开(公告)号：US20140350034A1
公开(公告)日：2014-11-27
申请号：US14371458
申请日：2013-01-25
申请人： Trixi Brandl , Stefanie Flohr , Christian Markert , Kenji Namoto , Bernard Pirard , Martin Renatus
发明人： Trixi Brandl , Stefanie Flohr , Christian Markert , Kenji Namoto , Bernard Pirard , Martin Renatus
IPC分类号： C07D498/04 , A61K31/519 , C07D405/12 , A61K31/443 , C07D487/04 , A61K31/4436 , C07D401/12 , A61K31/4439 , C07D213/73 , A61K31/44 , C07D495/04 , C07D409/12
CPC分类号： C07D498/04 , A61K31/44 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/519 , A61K45/06 , C07D213/73 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D487/04 , C07D495/04 , A61K2300/00
摘要： The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
摘要翻译： 本发明涉及式（I）化合物，其中取代基如说明书中所定义; 以游离形式或盐形式; 作为其制备，用作药物和包含它的药物。
-
3.发明申请Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 有权吡唑并吡啶衍生物作为β-肾上腺素能受体激酶1的抑制剂公开(公告)号：US20080227777A1
公开(公告)日：2008-09-18
申请号：US11961282
申请日：2007-12-20
申请人： Henning STEINHAGEN , Jochen HUBER , Kurt RITTER , Bernard PIRARD , Kirsten BJERGARDE , Marcel PATEK , Martin SMRCINA , Linli WEI
发明人： Henning STEINHAGEN , Jochen HUBER , Kurt RITTER , Bernard PIRARD , Kirsten BJERGARDE , Marcel PATEK , Martin SMRCINA , Linli WEI
IPC分类号： A61K31/5377 , C07D471/04 , A61P31/12 , A61P25/36 , A61K31/437
CPC分类号： C07D471/04
摘要： The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (βARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
摘要翻译： 本发明涉及可用作β-肾上腺素能受体激酶1（βARK-1）抑制剂的式（I）的6-酰氨基取代的吡唑并吡啶衍生物，含有这些化合物的组合物及其用于治疗和预防慢性心力衰竭，高血压的用途 ，心肌缺血和丙型肝炎病毒（HCV）感染，以及预防鸦片成瘾。
-
公开(公告)号：US20050004111A1
公开(公告)日：2005-01-06
申请号：US10751545
申请日：2004-01-05
申请人： Otmar Klingler , Reinhard Kirsch , Joerg Habermann , Klaus-Ulrich Weithmann , Christian Engel , Bernard Pirard
发明人： Otmar Klingler , Reinhard Kirsch , Joerg Habermann , Klaus-Ulrich Weithmann , Christian Engel , Bernard Pirard
IPC分类号： C07D239/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , A61K31/541 , A61K31/506 , A61K31/5377 , C07D413/02 , C07D417/02 , C07
CPC分类号： C07D239/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： The invention relates to a pyrimidine-4,6-dicarboxylic acid diamide compound, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use. Particularly, the pyrimidine-4,6-dicarboxylic acid diamide compound is useful for selectively inhibiting collagenase matrix metalloproteinase (MMP) 13, or for treating a degenerative joint disease.
摘要翻译： 本发明涉及嘧啶-4,6-二羧酸二酰胺化合物，包含其的药物制剂，其制备方法及其药物用途的方法。 特别地，嘧啶-4,6-二羧酸二酰胺化合物可用于选择性地抑制胶原酶基质金属蛋白酶（MMP）13或用于治疗退行性关节病。
-
公开(公告)号：US20100029636A1
公开(公告)日：2010-02-04
申请号：US12443229
申请日：2007-09-26
申请人： Peter Buehlmayer , Werner Breitenstein , Pascal Furet , Bernard Pirard , Anette von Matt , Thomas Zoller
发明人： Peter Buehlmayer , Werner Breitenstein , Pascal Furet , Bernard Pirard , Anette von Matt , Thomas Zoller
IPC分类号： A61K31/5377 , C07D487/04 , A61K31/4985 , C07D413/14 , A61P29/00
CPC分类号： C07D487/04
摘要： The invention relates to novel pyrazolo[1,5-A]pyrimidine compounds of Formula I in which all the variables are as defined in the specification; to their preparation and to their use as Lck kinase inhibitors.
摘要翻译： 本发明涉及其中所有变量如说明书中所定义的式I的新型吡唑并[1,5-A]嘧啶化合物。 用于制备和用作Lck激酶抑制剂。
-
公开(公告)号：US07235690B2
公开(公告)日：2007-06-26
申请号：US10132163
申请日：2002-04-26
IPC分类号： C07C311/04 , A61K31/18
CPC分类号： C07D207/335 , C07C311/08 , C07C311/21 , C07C311/29 , C07C311/44 , C07C2601/02 , C07C2601/14 , C07D213/40 , C07D213/64 , C07D215/12 , C07D231/12 , C07D231/16 , C07D233/56 , C07D233/64 , C07D235/14 , C07D249/08 , C07D277/28 , C07D307/14 , C07D307/52 , C07D405/12
摘要： The present invention is related to anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).
摘要翻译： 本发明涉及式I的邻氨基苯甲酰胺，其中R（1）至R（7）具有本文所述的含义，其制备方法，用作药物，以及含有它们的药物制剂。 化合物作用于Kv1.5钾通道并抑制在人心脏中心被称为超快速活化延迟整流器的钾电流。 因此，该化合物适合用作新的抗心律不齐剂，用于治疗和预防心律失常（例如心房颤动（AF）或心房扑动））。
-
7.发明授权公开(公告)号：US09290485B2
公开(公告)日：2016-03-22
申请号：US13194009
申请日：2011-07-29
申请人： Trixi Brandl , Stefanie Flohr , Sebastian Kopec , Julie Lachal , Christian Markert , Kenji Namoto , Perle Nganga , Bernard Pirard , Martin Renatus , Richard Sedrani , Thomas Zoller
发明人： Trixi Brandl , Stefanie Flohr , Sebastian Kopec , Julie Lachal , Christian Markert , Kenji Namoto , Perle Nganga , Bernard Pirard , Martin Renatus , Richard Sedrani , Thomas Zoller
IPC分类号： C07D401/14 , C07D409/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/14
CPC分类号： C07D409/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/14
摘要： The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
摘要翻译： 本发明涉及其中取代基如说明书中所定义的式I化合物; 以游离形式或盐形式; 作为其制备，用作药物和包含它的药物。
-
8.发明申请公开(公告)号：US20120035168A1
公开(公告)日：2012-02-09
申请号：US13194009
申请日：2011-07-29
申请人： Trixi BRANDL , Stefanie FLOHR , Sebastian KOPEC , Julie LACHAL , Christian MARKERT , Kenji NAMOTO , Perle NGANGA , Bernard PIRARD , Martin RENATUS , Richard SEDRANI , Thomas ZOLLER
发明人： Trixi BRANDL , Stefanie FLOHR , Sebastian KOPEC , Julie LACHAL , Christian MARKERT , Kenji NAMOTO , Perle NGANGA , Bernard PIRARD , Martin RENATUS , Richard SEDRANI , Thomas ZOLLER
IPC分类号： A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/4709 , C07D409/14 , C07D495/04 , A61K31/4365 , C07D413/14 , C07D471/04 , A61K31/444 , A61K31/536 , A61P3/10 , A61P27/02 , A61P9/12 , A61P27/12 , A61P9/10 , A61P25/00 , A61P31/00 , A61P25/16 , A61P25/08 , C07D401/12
CPC分类号： C07D409/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/14
摘要： The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
摘要翻译： 本发明涉及式I化合物，其中取代基如说明书中所定义; 以游离形式或盐形式; 作为其制备，用作药物和包含它的药物。
-
9.发明授权Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1 有权吡唑并吡啶衍生物作为β-肾上腺素能受体激酶1的抑制剂公开(公告)号：US07910602B2
公开(公告)日：2011-03-22
申请号：US11961282
申请日：2007-12-20
申请人： Henning Steinhagen , Jochen Huber , Kurt Ritter , Bernard Pirard , Kirsten Bjergarde , Marcel Patek , Martin Smrcina , Linli Wei
发明人： Henning Steinhagen , Jochen Huber , Kurt Ritter , Bernard Pirard , Kirsten Bjergarde , Marcel Patek , Martin Smrcina , Linli Wei
IPC分类号： A61K31/44 , A01N43/42 , C07D471/02 , C07D491/02 , C07D498/02 , C07D513/02
CPC分类号： C07D471/04
摘要： The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (βARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
摘要翻译： 本发明涉及可用作β-肾上腺素能受体激酶1抑制剂（＆Bgr; ARK-1）的式（I）的6-酰氨基取代的吡唑并吡啶衍生物，含有这些化合物的组合物及其用于治疗和预防慢性心力衰竭 ，高血压，心肌缺血和丙型肝炎病毒（HCV）感染以及预防鸦片成瘾。
-
10.发明授权Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases 有权嘧啶-4,6-二羧酸二酰胺，用于选择性抑制胶原酶公开(公告)号：US07166609B2
公开(公告)日：2007-01-23
申请号：US10700273
申请日：2003-11-03
申请人： Otmar Klingler , Reinhard Kirsch , Joerg Habermann , Klaus-Ulrich Weithmann , Christian Engel , Bernard Pirard
发明人： Otmar Klingler , Reinhard Kirsch , Joerg Habermann , Klaus-Ulrich Weithmann , Christian Engel , Bernard Pirard
IPC分类号： C07D239/54 , C07D403/12 , C07D403/14 , C07D413/12 , C07D417/12 , A61K31/506 , A61P19/02
CPC分类号： C07D239/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D471/04
摘要： Pyrimidine-4,6-dicarboxylic acid diamides of the formula I are suitable for selectively inhibiting collagenase (MMP 13). The pyrimidine-4,6-dicarboxylic acid diamides can therefore be used for treating degenerative joint diseases.
摘要翻译： 式I的嘧啶-4,6-二羧酸二酰胺适用于选择性抑制胶原酶（MMP 13）。 因此，嘧啶-4,6-二羧酸二酰胺可用于治疗退行性关节疾病。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.025 秒)
